Coherus Oncology (CHRS) Gains from Sales and Divestitures (2012 - 2025)

Coherus Oncology has disclosed Gains from Sales and Divestitures across 12 years of filings, most recently posting $528673.0 for Q4 2025.

• Gains from Sales and Divestitures for Q4 2025 came in at $528673.0, down 81.08% year-over-year; the trailing twelve-month figure through Dec 2025 was $528673.0 (down 81.08% YoY), and the FY2025 annual result was $528673.0, down 81.08% from the prior year.
• Gains from Sales and Divestitures came in at $528673.0 for Q4 2025 at Coherus Oncology, down from $2.8 million in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $2.8 million in Q4 2024 to a low of $465930.0 in Q4 2021.
• The 5-year median for Gains from Sales and Divestitures is $806854.0 (2022), against an average of $1.2 million.
• Across the five-year window, Gains from Sales and Divestitures soared 118.1% in 2024 and tumbled 81.08% in 2025, its largest moves.
• Coherus Oncology's Gains from Sales and Divestitures stood at $465930.0 in 2021, then jumped by 73.17% to $806854.0 in 2022, then surged by 58.75% to $1.3 million in 2023, then jumped by 118.1% to $2.8 million in 2024, then plunged by 81.08% to $528673.0 in 2025.
• The last three Gains from Sales and Divestitures figures came in at $528673.0 (Q4 2025), $2.8 million (Q4 2024), and $1.3 million (Q4 2023), per Business Quant data.